LRMR · XBRL financial data

Larimar Therapeutics financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (LRMR's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Research and development	31,407	38,396	24,250	27,670	73,278	154,224
General and administrative	11,397	12,069	12,276	14,088	17,612	18,273
Total operating expenses	42,804	50,465	36,526	41,758	90,890	172,497
Operating income (loss)	(42,804)	(50,465)	(36,526)	(41,758)	(90,890)	(172,497)
Income tax expense (benefit)	0	0	0	0	0	0
Net income (loss)	(42,482)	(50,636)	(35,355)	(36,949)	(80,604)	(165,673)
Earnings per share, basic USD per share	(3.57)	(2.95)	(1.37)	(0.84)	(1.32)	—
Earnings per share, diluted USD per share	(3.57)	(2.95)	(1.37)	(0.84)	(1.32)	—
Weighted average shares, basic thousands of shares	11,883	17,164	25,761	43,901	61,256	—
Weighted average shares, diluted thousands of shares	11,883	17,164	25,761	43,901	61,256	—

Fiscal years (LRMR's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	68,148	70,097	26,825	26,749	33,218	85,412
Marketable securities	24,490	—	91,603	60,041	150,236	51,440
Prepaid and other current assets	5,314	2,107	2,311	3,385	11,850	5,170
Total current assets	97,952	72,204	120,739	90,175	195,304	142,022
Property and equipment, net	1,040	1,049	831	684	881	622
Right-of-use asset	3,936	3,406	2,858	3,078	2,838	2,069
Total assets	104,686	78,667	126,405	95,935	200,225	145,842
Accounts payable	2,634	1,660	1,686	1,283	2,424	5,216
Accrued liabilities	5,843	6,592	8,408	7,386	20,872	58,474
Total current liabilities	8,992	8,846	10,705	9,506	24,356	64,795
Lease liability, non-current	6,002	5,408	4,797	4,709	4,057	2,962
Total liabilities	14,994	14,254	15,502	14,215	28,413	67,757
Accumulated deficit	(65,614)	(116,250)	(151,605)	(188,554)	(269,158)	(434,831)
Total stockholders' equity	89,692	64,413	110,903	81,720	171,812	78,085
Total liabilities and equity	104,686	78,667	126,405	95,935	200,225	145,842
Common shares outstanding (cover page) thousands of shares	15,368	17,710	43,269	63,800	64,028	103,883

Fiscal years (LRMR's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(42,482)	(50,636)	(35,355)	(36,949)	(80,604)	(165,673)
Stock-based compensation	2,161	5,473	6,619	7,615	8,796	7,004
Net cash from operating activities	(42,199)	(42,105)	(27,569)	(33,459)	(70,760)	(113,201)
Purchases of property and equipment	62	333	100	164	515	91
Net cash from investing activities	17,090	24,169	(90,960)	33,353	(85,387)	100,309
Proceeds from issuing common stock	75,592	19,885	75,257	—	161,806	65,086
Net cash from financing activities	93,587	19,885	75,257	30	161,883	65,086
Net change in cash	68,478	1,949	(43,272)	(76)	5,736	52,194

The peer list for this company is being put together from its industry's latest filings. Reload the page in a minute to see it.

Not investment advice. Not affiliated with the U.S. SEC.